Evaluating integrated supportive care pathways for cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PROACT is an observational cohort study designed to assess the implementation of integrated proactive supportive care pathways for cancer patients. The study focuses on measuring patient distress and supportive care needs using the NCCN Distress Thermometer over a 12-week period following an assessment. Secondary endpoints include evaluating the reach and diversity of the pathways, as well as their impact on overall health status, quality of life, symptom burden, anxiety, insomnia, and sexual health. The study aims to enhance the quality of care provided to cancer patients through structured supportive interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological confirmation of cancer (any cancer type, any stage)
* Age ≥ 18 years old
* Received an integrated supportive care need assessment.
* Sign the consent form for the PROACT study.

Exclusion Criteria:

* Absence or inability of written consent from the patient.
* Does not understand or speak French.

Where it's running

• Gustave Roussy
  Villejuif, France Recruiting

Study contacts

• Principal investigator: Ines VAZ LUIS — Gustave Roussy, Cancer Campus, Grand Paris
• Study coordinator: Maria Alice BORINELLI-FRANZOI
• Email: Mariaalice.BORINELLI-FRANZOI@gustaveroussy.fr
• Phone: +33 (0)1 42 11 42 11

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Cohort for people with chronic myelomonocytic leukemia

  This project will collect blood and bone marrow samples from adults with chronic myelomonocytic leukemia at diagnosis and during disease changes to create an anonymized biobank researchers can use to test new questions.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Amiens and 23 other locations · NCT07512882

• ASP3082 for advanced KRAS G12D non-small-cell lung and pancreatic cancers

  This study tests whether the experimental drug ASP3082, given once-weekly by IV, helps people with advanced or metastatic non‑small‑cell lung cancer or pancreatic ductal adenocarcinoma that carry a KRAS G12D mutation.

  Recruiting at 6 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, France and 6 other locations · NCT07483983

• Cutting down ultra-processed foods for people at high cancer risk

  This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Avignon and 2 other locations · NCT07436312

• Valemetostat for selected solid tumors with SWI/SNF gene alterations

  This trial will test whether valemetostat, an EZH1/2 inhibitor, can slow or stop growth in adults whose progressive solid tumors have specific SWI/SNF‑related gene changes.

  Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne and 3 other locations · NCT07303387

• Short-term preoperative elacestrant alone versus elacestrant plus ovarian suppression for premenopausal early-stage ER+/HER2- breast cancer

  We will test whether 4 weeks of elacestrant alone or with ovarian suppression lowers the tumor proliferation marker Ki67 in premenopausal women with stage I–II ER+/HER2- breast cancer.

  Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT07159451

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.